Figure 3.

BMSCs from AML patients are highly anti-inflammatory in vivo in an experimental model of acute severe colitis. Colitis was induced by intracolonic administration of TNBS and mice were treated i.p. with PBS (TNBS group), HD-BMSCs or AML-BMSCs (106 cells) 12 hours after TNBS injection. Control mice received 50% ethanol. Clinical evolution was monitored by determining the daily body weight loss (A) as well as measuring the colitis score at day 3 (B), survival (C) the macroscopic colonic damage score (D), and the histopathologic score at day 3 (E). Data are expressed as mean±s.e.m. n=10 mice per group in a-d. n=5 mice per group in e. Statistical differences between groups were calculated as described in the methods section. (F) Serum levels on the indicated cytokines in colitis mice treated with either HD- or AML-BMSCs. (G) Levels of IL6 and IL8 produced by in vitro expanded HD- and AML-BMSCs. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001.